OPTIMIZATION OF TKI TREATMENT IN ELDERLY PATIENTS WITH PH+ CHRONIC MYELOID LEUKEMIA AND STABLE MR3.0 OR MR4.0: 1ST YEAR RESULTS OF THE ITALIAN MULTICENTRIC PHASE-III RANDOMIZED OPTKIMA STUDY
Author(s): ,
Michele Malagola
Affiliations:
Chair of Hematology, Dept of Clinical and Experimental Sciences,University of Brescia, ASST Spedali Civili di Brescia,Brescia,Italy
,
Fabio Efficace
Affiliations:
Health Outcomes Research Unit, Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA), GIMEMA Data Center and Health Outcomes Research Unit,Rome,Italy
,
Nicola Polverelli
Affiliations:
Chair of Hematology, Dept of Clinical and Experimental Sciences,University of Brescia, ASST Spedali Civili di Brescia,Brescia,Italy
,
Francesco Cottone
Affiliations:
Health Outcomes Research Unit, Gruppo Italiano Malattie EMatologiche dell'Adulto (GIMEMA), GIMEMA Data Center and Health Outcomes Research Unit,Rome,Italy
,
Elisabetta Abruzzese
Affiliations:
Hematology, S Eugenio Hospital,, Tor Vergata University,Rome,Italy
,
Alessandra Iurlo
Affiliations:
Hematology Division, Foundation IRCCS Ca' Granda - Maggiore Policlinico,Milano,Italy
,
Cristina Bucelli
Affiliations:
Hematology Division, Foundation IRCCS Ca' Granda - Maggiore Policlinico,Milano,Italy
,
Fabio Stagno
Affiliations:
Department of Hematology, University of Catania,Catania,Italy
,
Massimiliano Bonifacio
Affiliations:
Department of Medicine, Section of Hematology, University of Verona,Verona,Italy
,
Mariella D'Adda
Affiliations:
Division of Hematology, ASST-Spedali Civili di Brescia,Brescia,Italy
,
Monia Lunghi
Affiliations:
Division of Hematology, Department of Translation Medicine, University of Eastern Piedmont,Novara,Italy
,
Monica Crugnola
Affiliations:
Hematology Unit, Maggiore Hospital University of Parma,Parma,Italy
,
Francesca Lunghi
Affiliations:
Hematology and Bone Marrow Transplantation (BMT) Unit, San Raffaele Scientific Institute,Milano,Italy
,
Fausto Castagnetti
Affiliations:
Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology and Medical Oncology 'L. & A. Seràgnoli', University of Bologna,Bologna,Italy
,
Gianantonio Rosti
Affiliations:
Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology and Medical Oncology 'L. & A. Seràgnoli', University of Bologna,Bologna,Italy
,
Maria Luisa Ferrari
Affiliations:
Hematology and Bone Marrow Transplant Unit, ASST Papa Giovanni XXIII,Bergamo,Italy
,
Micaela Bergamaschi
Affiliations:
Clinical Hematology, Ospedale Policlinico S. Martino, Istituto di Ricovero e Cura a Carattere Scientifico,Genova,Italy
,
Gianni Binotto
Affiliations:
Hematology and Clinical Immunology, Department of Medicine, Padua School of Medicine,Padova,Italy
,
Rosaria Sancetta
Affiliations:
Hematology Unit, Dell'Angelo Hospital,Venezia Mestre,Italy
,
Maria Rosaria Coppi
Affiliations:
Haematology and BMT Unit 'Antonio Perrino' Hospital,Brindisi,Italy
,
Valentina Giai
Affiliations:
Hematology Division, Azienda Ospedaliera Santi Antonio e Biagio e Cesare Arrigo,Alessandria,Italy
,
Giovanna Rege Cambrin
Affiliations:
Hematology Division, Ospedale Mauriziano,Torino,Italy
,
Atelda Romano
Affiliations:
Istituto Nazionale Tumori Regina Elena - IFO,Roma,Italy
,
Mario Tiribelli
Affiliations:
Division of Hematology and BMT, Department of Medical Area, University of Udine,Udine,Italy
,
Sabina Russo
Affiliations:
Division of Hematology, Dipartimento di Patologia Umana dell'Adulto e dell'Età Evolutiva, Policlinico G Martino, University of Messina,Messina,Italy
,
Lara Aprile
Affiliations:
Hematology Unit, Department of Medicine, Surgery and Neuroscience, Azienda Ospedaliera Universitaria Senese, University of Siena,Siena,Italy
,
Antonietta Pia Falcone
Affiliations:
Hematology Unit, IRCCS 'Casa Sollievo della Sofferenza',San Giovanni Rotondo,Italy
,
Serena Rupoli
Affiliations:
Hematology Clinical Unit, Ancona Hospital,Ancona,Italy
,
Antonella Russo Rossi
Affiliations:
Hematology and Transplants Unit, University of Bari,Bari,Italy
,
Emilio Usala
Affiliations:
Hematology Unit, Ospedale Oncologico A. Businco,Cagliari,Italy
,
Bruno Martino
Affiliations:
Hematology Unit Bianchi Melacrino Morelli Hospital,Reggio Calabria,Italy
,
Lisa Gandolfi
Affiliations:
Chair of Hematology, Dept of Clinical and Experimental Sciences,University of Brescia, ASST Spedali Civili di Brescia,Brescia,Italy
,
Simona Bernardi
Affiliations:
Chair of Hematology, Dept of Clinical and Experimental Sciences,University of Brescia, ASST Spedali Civili di Brescia,Brescia,Italy
,
Camilla Zanaglio
Affiliations:
Chair of Hematology, Dept of Clinical and Experimental Sciences,University of Brescia, ASST Spedali Civili di Brescia,Brescia,Italy
,
Mirko Farina
Affiliations:
Chair of Hematology, Dept of Clinical and Experimental Sciences,University of Brescia, ASST Spedali Civili di Brescia,Brescia,Italy
,
Michele Baccarani
Affiliations:
Department of Experimental, Diagnostic and Specialty Medicine, Institute of Hematology and Medical Oncology 'L. & A. Seràgnoli', University of Bologna,Bologna,Italy
Domenico Russo
Affiliations:
Chair of Hematology, Dept of Clinical and Experimental Sciences,University of Brescia, ASST Spedali Civili di Brescia,Brescia,Italy
EHA Library. malagola M. Jun 15, 2019; 267465; S882
Michele malagola
Michele malagola
Contributions
×
Abstract

Abstract: S882

Type: Oral Presentation

Presentation during EHA24: On Saturday, June 15, 2019 from 16:15 - 16:30

Location: Forum Hall

Background

The therapeutic strategy of CML in the TKIs era aims to improve the management of the disease and possibly also patients’ quality of life (QoL).

Aims

In July 2015, we started a prospective multicentric randomized trial with the aim to validate the policy of the intermittent de-escalation treatment and to examine the impact of this strategy on QoL.

Methods

To this purpose, CML patients older than 60 years in stable (≥2 years) MR3.0 or MR4.0 molecular response were randomized to receive a FIXED intermittent TKIs regimen (one month ON and one month OFF) (Russo D, Blood 2013; Russo D, BCJ 2015), versus a PROGRESSIVE intermittent TKIs regimen (one month ON and one month OFF for the 1st year; one month ON and two months OFF for the 2nd year; one month ON and three months OFF from the 3rd year) (OPTkIMA study, ClinicalTrials.gov: NCT02326311). Molecular monitoring was performed according to the 2015 ELN guidelines (Baccarani M, Blood2013). In case of confirmed MR3.0 (MMR) loss, patients were planned to exit the study and to resume TKIs daily. QoL was evaluated at baseline, every three months during the first year and regularly thereafter, using the well validated EORTC QLQ-C30 and its CML module (EORTC QLQ-CML24) as well as the EORTC Elderly Module (EORTC QLQ-ELD14). For the purpose of this preliminary QoL analysis we only considered changes from baseline up to 12 months, that is when both patient groups receive the same treatment schedule (one month ON and one month OFF).

Results

This first interim report, have been focused on the patients who, by intention to treat, have completed the first year of the study. Up to December 2018, 186 patients have been enrolled by 26 Italian Hematological Centers and 166/186 patients (89%) completed the first year of OPTkIMA study. The median age was 71 years (range 60-89) and 66% of the patients were belonging to the Sokal intermediate/high risk goup. 129/166 (77%) patients were receiving imatinib (IMA). Overall, 89/166 (54%) and 77/166 (46%) patients have been randomized in the FIXED and PROGRESSIVE arm, respectively. 46/76 patients (61%) randomly assigned to the PROGRESSIVE arm have entered the second year of therapy. 47/166 patients (28%) went out of the study during the first year (Table 1). 39/166 cases (23%) lost MR3.0. Thus the probability of loosing the MR3.0 while on OPTkIMA was 19% at one year (Figure 1). All the 39 patients resumed TKIs continuously and all obtained at least the MR3.0 response, within 6 months. The intermittent treatment was well tolerated, with 7 serious adverse events, none of which treatment-related. None of the patients experienced the TKI withdrawn syndrome. QoL analysis was based on 166 patients with currently available QoL data. The top three most prevalent baseline symptoms (EORTC QLQ-C30) were fatigue (80%), pain (51%) and sleep disturbance (48%). With regard to QoL disease-specific domains (EORTC QLQ-CML24), no statistically significant changes were noted during the first year of treatment. Further QoL analyses are currently ongoing.

Conclusion

According to this first interim report, we found that a policy of intermittent TKIs administration in elderly patients is safe and well tolerated. After the 1st year, 28/166 patients (23%) lost MR3.0 and all of them re-gained the major molecular response within 6 months from resumption of continuous treatment. Thus, the probability of MR3.0 loss while on OPTkIMA at 1 year was 19%, comparable to the 20% of the previously published INTERIM trial.

Acknowledgements: GIMEMA CML WP, ELN, COFIN2009

Session topic: 8. Chronic myeloid leukemia - Clinical

Keyword(s): Molecular response, Quality of life, Tyrosine kinase inhibitor

By continuing to browse or by clicking “Accept Terms & all Cookies”, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies